Analysts see USD 17 target for Seres Therapeutics stock
Published on 10/08/2026 at 10:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Seres Therapeutics (US81750R2013) was trading at EUR 2.44 at Lang & Schwarz on October 8, 2026, at 10:36 a.m. CEST, plus 0.41 percent versus EUR 2.43. A Simply Wall St narrative published October 6 put the analyst consensus target at USD 17.00.
USD 17 target meets funding risk
The target narrative values Seres Therapeutics against a clinical pipeline centered on live biotherapeutics, including SER-155 for immune-related enterocolitis and infection prevention. The article also cites historical cash and cash equivalents of USD 45.8 million as of December 31, 2025, with an operating runway extending through the third quarter of 2026.
That contrast matters for the stock. The same Simply Wall St analysis says additional funding or partnerships are needed to advance SER-155 into later trials, while its consensus model assumes revenue will decline 39.90 percent annually over the next three years.
Nasdaq range shows a wide gap
On the Nasdaq, the stock's 52-week range was USD 2.70 to USD 29.98 as of October 7, 2026. Finance data also put Seres Therapeutics' market capitalization at USD 26.3 million and its one-year change at minus 86.15 percent, figures that frame the USD 17.00 target as a high-risk valuation scenario rather than a near-term operating result.
Seres Therapeutics is a clinical-stage biotechnology company developing therapies that target disruptions in the gastrointestinal microbiome. Its pipeline includes SER-155 and SER-603, while the company's investor-relations page identifies July 2026 clinical data as its latest listed news.
November results set the next marker
MarketBeat lists November 4, 2026, for Seres Therapeutics' third-quarter results and an earnings call before the market opens. The scheduled report may give investors a clearer read on cash use, revenue and the funding required for the development pipeline.
For now, the market picture combines a EUR 2.44 Lang & Schwarz indication with a USD 17.00 analyst consensus target. The separate currencies prevent a direct percentage comparison, but the operating runway and planned results date identify the figures that matter next.
The further course of trading is shown by the continuously updated real-time quote of Seres Therapeutics stock.
Seres Therapeutics market data
- Company: Seres Therapeutics, Inc.
- ISIN: US81750R2013
- Ticker: MCRB
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 8, 2026, 10:36 a.m. CEST): EUR 2.44
- Change versus prior close: plus 0.41 percent
- Prior close Lang & Schwarz (October 7, 2026): EUR 2.43
- Market capitalization: USD 26.3 million (as of October 7, 2026)
- 52-week range: USD 2.70-USD 29.98 (as of October 7, 2026)
- Sector / Industry: Healthcare / Biotechnology
